Hcp1-loaded staphylococcal membrane vesicle vaccine protects against acute melioidosis

Burkholderia pseudomallei is the causal agent of melioidosis, a deadly tropical infectious disease that lacks a vaccine. On the basis of the attenuated Staphylococcus aureus RN4220-Delta agr (RN), we engineered the RN4220-Delta agr/pdhB-hcp1 strain (RN-Hcp1) to generate B. pseudomallei hemolysin-coregulated protein 1 (Hcp1)-loaded membrane vesicles ((hcp1)MVs). The immunization of BALB/c mice with (hcp1)MVs mixed with adjuvant by a three-dose regimen increased the serum specific IgG production. The serum levels of inflammatory factors, including TNF-alpha and IL-6, in (MV)-M-hcp1-vaccinated mice were comparable with those in PBS-challenged mice. The partial adjuvant effect of staphylococcal MVs was observed with the elevation of specific antibody titer in (MV)-M-hcp1-vaccinated mice relative to those that received the recombinant Hcp1 protein (rHcp1) or MVs derived from RN strain ((Delta agr)MVs). The (hcp1)MVs/adjuvant vaccine protected 70% of mice from lethal B. pseudomallei challenge. Immunization with (hcp1)MVs only protected 60% of mice, whereas vaccination with rHcp1 or (Delta agr)MVs conferred no protection. Moreover, mice that received (hcp1)MVs/adjuvant and (hcp1)MVs immunization had low serum TNF-alpha and IL-6 levels and no inflammatory infiltration in comparison with other groups. In addition, all surviving mice in (hcp1)MVs/adjuvant and (hcp1)MVs groups exhibited no culturable bacteria in their lungs, livers, and spleens five days postinfection. Overall, our data highlighted a new strategy for developing B. pseudomallei vaccine and showed that Hcp1-incorporated staphylococcal MV is a promising candidate for the prevention of acute melioidosis.